Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Isabelle Dang Timba Babagna

Treatment of Viral Hepatitis C by the Sofosbuvir and Ledipasvir With or Without Ribavirin Combination in Cameroon: Efficiency, Tolerance and Significant Predictors of SVR12

Clinical Infection and Immunity

2018

English

Related publications

Kidney Transplant Recipients With Hepatitis C Virus Experienced 100% SVR12 Rate When Treated With Sofosbuvir-Ledipasvir

English

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Digestive Diseases and Sciences

Physiology

Gastroenterology

2016

English

Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4

Alimentary Pharmacology and Therapeutics

English

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

English

Ledipasvir and Sofosbuvir for Recurrent Hepatitis C After Liver Transplantation

English

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

JAMA - Journal of the American Medical Association

Medicine

2014

English

Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis Treated With a Simeprevir/Sofosbuvir/Ledipasvir Regimen

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2017

English

Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus

English

Sofosbuvir and Ledipasvir in Attainment of SVR12 in Sickle Cell Disease (SCD) Sub-Population With Chronic Hepatitis C (CHC). A Single Center Prospective Study-Slash C Trial

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Isabelle Dang Timba Babagna

Treatment of Viral Hepatitis C by the Sofosbuvir and Ledipasvir With or Without Ribavirin Combination in Cameroon: Efficiency, Tolerance and Significant Predictors of SVR12

Related publications

Kidney Transplant Recipients With Hepatitis C Virus Experienced 100% SVR12 Rate When Treated With Sofosbuvir-Ledipasvir

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Sofosbuvir Plus Daclatasvir With or Without Ribavirin in 551 Patients With Hepatitis C-Related Cirrhosis, Genotype 4

Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients

Ledipasvir and Sofosbuvir for Recurrent Hepatitis C After Liver Transplantation

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis Treated With a Simeprevir/Sofosbuvir/Ledipasvir Regimen

Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus

Sofosbuvir and Ledipasvir in Attainment of SVR12 in Sickle Cell Disease (SCD) Sub-Population With Chronic Hepatitis C (CHC). A Single Center Prospective Study-Slash C Trial